An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
Study of TAK-079 and Backbone Regimens in Patients with Newly Diagnosed Multiple Myeloma
Sponsor: Millennium Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS5276
U.S. Govt. ID: NCT03984097
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study will look to obtain information on the best dose of the research drug, TAK 079, when administered in combination with other approved multiple myeloma treatments for patients with newly diagnosed multiple myeloma. If you participate you will receive either Arm A (TAK-079 in combination with lenalidomide and dexamethasone) or Arm B (TAK-079 in combination with bortezomib, lenalidomide and dexamethasone).
This study is closed
Investigator
Divaya Bhutani, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with multiple myeloma (MM)? Yes No
Is your multiple myeloma (MM) previously untreated? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE